celeron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in five abstracts for sotatercept and ACE-536, Acceleron’s programs to treat red blood cell disorders, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition.
Help employers find you! Check out all the jobs and post your resume.
